{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8"}]}],"title":"Percentage of participants with CR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Percentage of participants with PR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.3"}]}],"title":"Percentage of participants with mCR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"}],"units":"Participants"}],"description":"As per the IWG Response Criteria 2006, CR was defined as Bone marrow: ≤5% myeloblasts with normal maturation of all cell lines; Peripheral blood (PB): Hb ≥11 g/dL; platelets ≥100 x 10\\^9/dL; neutrophils ≥1.0 x 10\\^9/liter; blasts: 0%. PR was defined as Bone marrow: ≤5% myeloblasts and decrease by ≥50% over pretreatment; cellularity and morphology not relevant. mCR was defined as Bone marrow: ≤5% myeloblasts and decreased by ≥50% over pre-treatment PB. Percentages were rounded off to the nearest single decimal place. All participants in Phase 2 were evaluated by the Investigator for CR/PR/mCR regardless of bone marrow blasts at baseline.","groups":[{"description":"Imetelstat sodium administered IV, at a starting dose of 7.5 mg/kg, every 4 weeks (on a 28-day cycle) until death, lost to follow-up, withdrawal of consent, or study termination whichever occurs first. Dose escalation to 9.4 mg/kg was allowed before Protocol Amendment 2.","id":"OG000","title":"Phase 2: Imetelstat Sodium"}],"paramType":"NUMBER","populationDescription":"Phase 2: All Treated Analysis Set included all participants who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"Up to 5 years in Phase 2","title":"Phase 2: Percentage of Participants With Complete Remission (CR), Partial Remission (PR), or Marrow Complete Remission (mCR) as Per International Working Group (IWG) Response Criteria 2006 as Assessed by the Investigator","type":"SECONDARY","unitOfMeasure":"percentage of participants"}